Cutera - CUTR Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CUTR shares.
View CUTR analyst ratings or view top-rated stocks.

5 equities research analysts have issued 1 year price targets for Cutera's shares. Their CUTR share price forecasts range from $33.00 to $70.00. On average, they anticipate the company's stock price to reach $56.20 in the next year. This suggests a possible upside of 61.4% from the stock's current price.
View analysts price targets for CUTR or view top-rated stocks among Wall Street analysts.

Cutera's stock was trading at $44.22 on January 1st, 2023. Since then, CUTR shares have decreased by 21.2% and is now trading at $34.83.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our CUTR earnings forecast.

Cutera, Inc. (NASDAQ:CUTR) issued its earnings results on Thursday, November, 3rd. The medical device company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.38. The medical device company had revenue of $62.81 million for the quarter, compared to the consensus estimate of $62.65 million. Cutera had a negative trailing twelve-month return on equity of 225.70% and a negative net margin of 31.31%.

Cutera updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $252.00 million-$253.00 million, compared to the consensus revenue estimate of $259.00 million.

1 employees have rated Cutera Chief Executive Officer David H. Mowry on Glassdoor.com. David H. Mowry has an approval rating of 100% among the company's employees. This puts David H. Mowry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include NVIDIA (NVDA), QUALCOMM (QCOM), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), DocuSign (DOCU), Pfizer (PFE), Block (SQ) and Twilio (TWLO).

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

Cutera's stock is owned by many different institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (0.39%), Greenwood Capital Associates LLC (0.15%), Calamos Advisors LLC (0.14%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David H Mowry, J Daniel Plants, Joseph E Whitters, Katherine S Zanotti, Rohan Seth and Timothy J Oshea.
View institutional ownership trends.

Shares of CUTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CUTR stock can currently be purchased for approximately $34.83.

Cutera (NASDAQ:CUTR) has a market capitalization of $683.02 million and generates $231.27 million in revenue each year. The medical device company earns $2.06 million in net income (profit) each year or ($4.21) on an earnings per share basis.

The company employs 461 workers across the globe.

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The official website for the company is www.cutera.com. The medical device company can be reached via phone at (415) 657-5500, via email at ir@cutera.com, or via fax at 415-330-2444.